- Home
- STRS vs AMRN Comparison
STRS vs AMRN Comparison
Compare STRS & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRS
- AMRN
- Stock Information
- Founded
- STRS 1992
- AMRN 1989
- Country
- STRS United States
- AMRN Ireland
- Employees
- STRS N/A
- AMRN N/A
- Industry
- STRS Homebuilding
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- STRS Real Estate
- AMRN Health Care
- Exchange
- STRS Nasdaq
- AMRN Nasdaq
- Market Cap
- STRS 202.0M
- AMRN 234.4M
- IPO Year
- STRS N/A
- AMRN 1993
- Fundamental
- Price
- STRS $24.35
- AMRN $0.57
- Analyst Decision
- STRS
- AMRN Hold
- Analyst Count
- STRS 0
- AMRN 3
- Target Price
- STRS N/A
- AMRN $1.00
- AVG Volume (30 Days)
- STRS 8.7K
- AMRN 723.4K
- Earning Date
- STRS 11-12-2024
- AMRN 10-30-2024
- Dividend Yield
- STRS N/A
- AMRN N/A
- EPS Growth
- STRS N/A
- AMRN N/A
- EPS
- STRS N/A
- AMRN N/A
- Revenue
- STRS $42,935,000.00
- AMRN $264,779,000.00
- Revenue This Year
- STRS N/A
- AMRN N/A
- Revenue Next Year
- STRS N/A
- AMRN N/A
- P/E Ratio
- STRS N/A
- AMRN N/A
- Revenue Growth
- STRS 31.68
- AMRN N/A
- 52 Week Low
- STRS $20.30
- AMRN $0.56
- 52 Week High
- STRS $30.66
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- STRS 47.47
- AMRN 41.50
- Support Level
- STRS $22.84
- AMRN $0.56
- Resistance Level
- STRS $24.72
- AMRN $0.61
- Average True Range (ATR)
- STRS 1.18
- AMRN 0.03
- MACD
- STRS -0.09
- AMRN -0.00
- Stochastic Oscillator
- STRS 37.65
- AMRN 2.44
About STRS Stratus Properties Inc.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.